SGC Open Notebook Project to Characterize the HMTase NSD3 Exp026 Objective: NSD3 is frequently amplified as part of the 8p11-12 focal amplification in several types of cancer. Here we set out to explore the gene expression profiles of NSD3 amplified versus non-amplified lung squamous cancer samples from the TCGA. However, because this event takes place in the context of a focal amplification we will also compare samples with high versus low NSD3 expression. The goal of this experiment is to identify putative oncogenic signalling pathways NSD3 may regulate, as well as inform on the biological role of this protein in the context of gene expression.

Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.